Cannabis has remarkable therapeutic potential, but its clinical use is limited by the psychotropic activity of Δ 9 -tetrahydrocannabinol (Δ 9 -THC). Surprisingly, the biological profile of the non-narcotic native precursor of Δ 9 -THC (Δ 9 -THC acid A, Δ 9 -THCA-A) is still largely unexplored. We present evidence that Δ 9 -THCA-A is a partial and selective PPARγ modulator, endowed with lower adipogenic activity than the full PPARγ agonist rosiglitazone 30 (RGZ) and with an enhanced osteoblastogenic activity in human mesenchymal stem cells.
INTRODUCTION 75
Preparations of Cannabis sativa have been used since the earliest written records of medical history, complementing the nutritional and technological uses of the plant and contributing to make it one of the first species cultivated by humans. Modern studies as well as anecdotal reports suggest the potential efficacy of cannabis extracts and cannabinoids in different medical conditions. Almost 150 cannabinoids have been isolated from different strains of 80 Cannabis (1) with Δ 9 -tetrahydrocannabinol (Δ 9 -THC) and cannabidiol (CBD) being the best investigated class members from a medical standpoint. These neutral cannabinoids are produced and stored in the plant as acidic precursors (cannabinoid acids) (2) . Decarboxylation requires heating but can take place also at room temperature upon prolonged storage of Cannabis (3) . Remarkably, the acidic precursor of Δ 9 -THC (Δ 9 -THCA-A) is not psychotropic, 85 and its binding to cannabinoid receptors is highly controversial and probably associated to contamination by its decarboxylation product (4) . On the other hand, we recently showed that THCA-A, but not its decarboxylation product Δ 9 -THC, is a potent activator of the peroxisome proliferator-activated receptor-γ (PPARγ) endowed with remarkable neuroprotective activity (5) . In agreement with these findings, the PPARγ activating properties of a Cannabis extract 90 with a high titer of Δ 9 -THC was greatly reduced by decarboxylation (5) . Given the key metabolic roles of PPARγ, these findings provided a rationale to investigate the possibility that Δ 9 -THCA-A based therapies could be beneficial for the management of metabolic disorders.
Obesity has reached pandemic proportions worldwide, with more than 650 million obese 95 and nearly 2 billion people being overweighed (6) . Obesity is a major risk factor for the development of multiple diseases, including prominently cardiovascular and metabolic disorders, such as type-2 diabetes and metabolic syndrome (MetS) (7, 8), but also respiratory, osteoarticular, cognitive, reproductive and oncologic pathologies (9) (10) (11) (12) . The basis for the multi-organ alterations seen in obesity remains unfolded (13), but the state of chronic, low-100 grade inflammation commonly associated to this condition is considered a major contributing factor (11). This is reflected by the increased concentrations of white adipose tissue-derived pro-inflammatory cytokines (TNF-α, IL-6, leptin) and the antiparallel decrease of antiinflammatory signals, as adiponectin, commonly observed in obesity (12, 14, 15) . Additional hormonal perturbations, e.g., of gastro-intestinal factors, such as ghrelin and GLP-1 (16) , as 105 well as the ectopic deposition of fat, mostly in the liver (i.e., steatosis), which defines a state of lipotoxicity (17), contribute also to the worsening of the metabolic profile of obese 6 patients. In view of the conspicuous lack of effective therapies for the integral management of obesity, considerable attention is currently given to the identification of novel pharmacological agents globally targeting its deregulated substrates and other related 110 pathways, as thermogenesis, to regain energy homeostasis (18) (19) (20) .
In fact, while initial strategies to tackle obesity were mostly focused in the control of food intake, growing interest has been paid recently to elucidate the physiological roles and eventual therapeutic use of adaptive thermogenesis in the control of body weight and energy homeostasis (21, 22) . Studies in this area have been directed not only to the brown adipose 115 tissue (BAT), where canonical adaptive thermogenesis occurs in mammals, including humans (23) , but also to the capacity of the white adipose tissue (WAT) to undergo, under certain conditions, browning, a process whereby adipocyte precursor cells acquire brown-like features, becoming beige or brite adipocytes (24) . Brown and beige adipocytes are defined by a large set of mitochondria and high expression of uncoupling protein-1 (UCP-1), as major 120 molecular switch to enhance heat dissipation at the expense of lower ATP synthesis at the respiratory chain (25) . Thermogenic activity is finely regulated by the direct actions of a large set of circulating hormones, from adipokines to sex steroids and thyroid hormones (23, 26) , as well as the adrenergic input from the sympathetic nervous system (27) , therefore being amenable for pharmacological manipulation. 125
PPARγ is a nuclear receptor that plays key role in regulating a number of biological functions including lipid and glucose metabolism (28) . PPARγ is also involved in the natural and adaptive immune response as well as in additional biological activities like the browning of white fat (29) . PPARγ ligands include a wide array of natural and synthetic molecules, with glitazones, a class of compounds extensively for the management of type-2 diabetes, being 130 the archetypal activators. Glitazones, like rosiglitazone (RGZ), are considered full PPARγ ligand agonists, and this profile is inextricably associated to both antidiabetic activity and undesirable side effects like weight gain, edema, and osteoporosis (30) . Furthermore, liver injury, cancer, as well as an increased risk of heart failure have also been associated with the long-term use of glitazones (30) . However, while the therapeutic potential of PPARγ ligand 135 agonist remains high, interest has substantially shifted towards partial ligands, preeminent examples of which are natural products such as armofrutins and acidic cannabinoids (5, 31) .
Depending on the mode of interaction and binding to the ligand-binding domain (LBD) of PPARγ (32, 33) , modulators can induce graded responses, such as full-and partial agonism and antagonism. Thus, the recent identification of a functional alternative binding site for 7 PPARγ ligands that does not fully overlap with the canonical glitazone binding site (34) has opened novel research avenues for the identification and/or development of second-generation PPARγ agonists.
RESULTS

Δ 9 -THCA-A is a selective and non-adipogenic PPARγ ligand agonist that induces iWAT browning through a PPARγ-dependent pathway
We have previously shown that Δ 9 -THCA-A is a PPARγ agonist at nanomolar concentrations (5) . Herein, we have studied the selectivity of Δ 9 -THCA-A on different 150
PPARs, showing that, when compared to the full ligand agonist rosiglitazone (RGZ), Δ 9 -THCA-A is only a partial ligand activator for PPARγ, devoid of PPARα and PPARδ transcriptional activities ( Fig. 1A) . Dephosphorylation of PPARγ at Ser273 is essential for acquiring insulin-sensitizing activity (35), and we found that, in 3T3-L1 adipocytes, Δ 9 -THCA-A, as well as RGZ, could inhibit the TNFα-induced Ser273 155 phosphorylation of PPARγ ( Fig. 1B) .
PPARγ has a large and dynamic LBD, whose diversity of ligand accommodation in its two sub-pockets is associated to distinct biological activities (32) . Based on the structure of different PPARγ-ligand complex, it has been proposed that full agonists bind to both subpockets, establishing hydrogen bonds with residues Tyr473 (H12) on AF-2 (also called 160 orthosteric or canonical binding site) and Ser342 (S1/S2) on β-sheet sub-pocket (also called alternative binding site), whereas partial agonists can preferentially bind to the alternative site (34) . Docking analysis suggested that Δ 9 -THCA-A binds both the canonical (Ser289) and the alternative binding sites (L340 and Ser342) in LBD (Fig. S1) . The functionality of both LBD sites in the response to Δ 9 -THCA-A was therefore investigated. To this purpose, T0070907, a 165
PPARγ antagonist that binds irreversibly to the canonical binding site, was used. First, luciferase reporter assays were used to study the participation of the canonical and alternative binding sites in the response to Δ 9 -THCA-A in comparison with RGZ. As expected, preincubation with T0070907 effectively blocked RGZ-induced PPARγ transactivation (Fig.   1C ). Conversely, T0070907 could not block Δ 9 -THCA-A-induced PPARγ transcriptional 170 activity ( Fig. 1D) . In addition, T0070907 almost fully suppressed the expression of PPARγdependent genes induced by RGZ in human mesenchymal stem cells (MSCs) differentiated to adipocytes ( Fig. 1E) . Conversely, T0070907 did not fully prevent the effect of Δ 9 -THCA-A on these genes ( Fig. 1F) . By using time-resolved fluorescence resonance energy transfer (TR-FRET) co-regulator interaction assays, we found that RGZ increases the binding of peptides 175 derived from TRAP220 and PGC-1α, but decreases the binding of peptides derived from NCoR and SMRT. In contrast, Δ 9 -THCA-A has not significant effect on the recruitment TRAP220 to PPARγ and showed only a moderate effect on the recruitment of PGC-1α. Indeed, Δ 9 -THCA-A had a weak effect to displace corepressors from the binding to PPARγ (Fig. S2) . 180
To further investigate the role of the PPARγ canonical binding site in vivo, mice were treated with Δ 9 -THCA-A in the presence or not of T0070907, performing transcriptomic analysis in inguinal white adipose tissue (iWAT), a major target organ for PPARγ agonists.
The comparative differential expression analysis of both conditions versus control mice resulted in a total of 3719 genes with an adjusted P ≤ 0.01 and an absolute fold change ≥ 2 185 ( Fig. 2A ). From them, 72 genes belonging to the PPARγ signaling and thermogenesis pathways were upregulated in response to Δ 9 -THCA-A ( Fig. 2A-B ). Within this group of genes, the co-treatment with T0070907 prevented the upregulation of 46 genes induced by Δ 9 -THCA-A and 26 genes were unaffected (Fig. 2C) . In contrast, genes included in the NF-κB signaling pathway were not affected by Δ 9 -THCA-A treatment, but significantly increased 190 their expression in animals co-treated with T0070907 ( Fig. 2A-B ). Uncoupling protein 1 (UCP-1) gene, a key marker of the iWAT browning process, was found among the top 25 genes upregulated by Δ 9 -THCA-A in a T0070907-sensitive manner ( Fig. 2D) . Moreover, western blotting and immunohistochemistry showed that Δ 9 -THCA-A induced the expression of UCP-1 protein in iWAT ( Fig. 2E) . In line with such putative thermogenic activation, Δ 9 -195 THCA-A treatment caused a suppression of body weight that was independent of food intake changes but blocked by co-administration of T0070907 ( Fig. S3) .
In our analysis, we also found 317 genes that were modified by Δ 9 -THCA-A in a way insensitive to T0070907 (Fig. S4A) . To functionally evaluate this cluster of genes, we performed an over-representation analysis using the KEGG pathways and Gene Ontology 200 annotations after sorting them out into up-and down-regulated ones ( Fig. S4B-C) .
Interestingly, a set of upregulated genes associated to fatty acid metabolism was found.
Conversely, genes belonging to cGMP-PKG, to calcium signaling pathways, and to muscle tissue development were downregulated by Δ 9 -THCA-A administration. Taken together, our results showed that the bioactivity of Δ 9 -THCA-A was mediated by the PPARγ canonical 205 pathway as well as by pathways mediated by the alternative binding site of this nuclear receptor.
PPARγ partial ligand agonists are thought to be less adipogenic than full ligand agonists and are also expected to have fewer negative effects on bone metabolism. Therefore, we studied the ability of Δ 9 -THCA-A to influence MSCs differentiation into adipocytes and 210 osteoblasts. MSCs were cultured in adipogenic medium (AM) for either 14 days or 21 days to evaluate the mRNA expression of adipogenic markers and to detect lipid droplets. Fig. 3A-B show that MSC treated with Δ 9 -THCA-A contained fewer and smaller lipid droplets compared to RGZ treatment. Moreover, Δ 9 -THCA-A induced lower expression of the adipogenic differentiation markers PPARγ, aP2a, ADIPOQ, LPL and CEBPA, as compared to 215 cells treated with RGZ ( Fig. 3C) . Remarkably, we found that, in MSC differentiated in an osteoblastogenic medium, Δ 9 -THCA-A enhanced osteoblast mineralization as well as the expression of the osteogenic differentiation markers Runx2, SP7, IBS and ALP, ( Fig. 3D-F) .
These data indicate that Δ 9 -THCA-A qualifies as a partial PPARγ ligand significantly less adipogenic than RZG and with an enhanced osteoblasts differentiation capacity. 220 Repeated administration of Δ 9 -THCA-A caused a marked suppression of BW gain in HFD 230 mice ( Fig. 4B) , as observed, albeit with lesser amplitude, in CD mice. The increased adiposity caused by HFD was similarly restored by chronic Δ 9 -THCA-A treatment, which caused also a significant suppression of the adiposity index in control lean mice ( Fig. 4C) .
Administration of Δ 9 -THCA-A for 3-wks improved also glucose homeostasis in HFDinduced obese mice. Thus, while HFD exposure for 15-wks evoked an elevation of basal 235 glucose levels, worsened glucose tolerance after glucose bolus injection ( Fig. 4D ) and reduced insulin sensitivity ( Fig. 4E) , treatment of HFD mice with Δ 9 -THCA-A for 3-wks resulted in lowering of basal glycemia, and markedly improved glucose profiles, both in glucose and insulin tolerance tests, which displayed better profiles than those of CD mice without pharmacological intervention. Moreover, positive effects of Δ 9 -THCA-A in terms of 240 glucose tolerance and insulin sensitivity were also detected in lean control mice ( Fig. 4D-E ).
This was associated to a significant lowering of basal insulin levels after Δ 9 -THCA-A administration to CD and HFD mice ( Fig. 4F) , possibly reflecting a state of enhanced insulin sensitivity. In the same line, Δ 9 -THCA-A treatment of obese mice largely prevented liver fat infiltration caused by HFD and markedly reduced the steatosis score ( Fig. 4G-H) . In good 245 agreement with these observations, Δ 9 -THCA-A significantly decreased serum triglyceride levels both in obese and lean mice (Fig. 4I) .
The iWAT transcriptomic profile in control and HFD mice, untreated or treated with Δ 9 -THCA-A, was next investigated. A differential expression analysis revealed a total of 1387 genes overcoming the cutoff of an adjusted P ≤ 0.01 and an absolute fold change ≥ 2 in any of 250 the two comparisons ( Fig. 5A) . Among them, KEGG pathway analyses revealed that genes involved in NF-κB signaling and cytokine-cytokine receptor were upregulated in HFD mice, which matches the inflammatory phenotype in iWAT that accompanies the metabolic syndrome (36) . Additionally, genes belonging to the insulin receptor signaling pathway showed a lowered expression in HFD mice, in agreement with the hallmark state of insulin 255 resistance of obesity. Interestingly, Δ 9 -THCA-A treatment in HFD mice reduced the expression of genes belonging to the inflammatory pathways, partially recovering the expression of those linked to the insulin signaling process ( Fig. 5A-B) . In total, DEGs analysis revealed that 1014 genes including those related to NF-κB signaling and cytokinecytokine receptor (70 genes) were modified in HFD mice and normalized in Δ 9 -THCA-A-260 treated HFD mice ( Fig. 5C ). Finally, to confirm the anti-inflammatory profile of Δ 9 -THCA-A, we analyzed by qPCR assays the top 25 upregulated inflammatory genes in the iWAT of HFD mice ( Fig. 5D) , confirming the increased expression of key components of this gene set, including TNFα, ICAM-1, CD4, CXCL-16, CCK22, CXCR5 and CXCR2 (Fig. 5E) .
In keeping with their obese phenotype, HFD mice also displayed features of adipose 265 tissue enlargement and inflammation. Thus, a significant increase in adipocyte volume was observed, accompanied by signs of macrophage infiltration of white adipose tissue (WAT), assessed by F4/80 staining of clusters of macrophages surrounding dead adipocytes, in the socalled crown-like structures (CLS) ( Fig. 6A-B) . Notably, Δ 9 -THCA-A administration for 3wks fully prevented adipocyte enlargement and the appearance of CLS in the inguinal WAT 270 of HFD-induced obese mice. Moreover, a substantial upsurge in the levels of the thermogenic protein, UCP-1, in the iWAT of obese mice was also observed ( Fig. 6A-C) .
Finally, changes in the circulating levels of key metabolic hormones were assessed in HFD-induced obese mice, treated or not with Δ 9 -THCA-A. In line with their obese phenotype, HFD mice showed increased leptin and glucagon levels, and decreased GLP-1 concentrations 275 vs. lean CD animals. Treatment with Δ 9 -THCA-A for 3-wks fully normalized leptin, GLP-1 and glucagon levels, and evoked a significant increase in adiponectin concentrations ( Fig. 6D-G ). In the same vein, proteome profiler arrays targeting a comprehensive set of circulating adipokines and cytokines confirmed the increase of the levels of leptin, together with other adipose born-factors, such as Oncostatin M and Serpin E1, in HFD mice, which were decreased 280 by Δ 9 -THCA-A, while adiponectin concentrations were increased. Likewise, a set of cytokines including Endostatin, IGFBp-5, PCSK9, Adipsin and IGFBP-3 were suppressed by HFD but increased by Δ 9 -THCA-A in HFD mice, while an opposite pattern was observed for CCL11 and CCL6 ( Fig. 6I) .
285
DISCUSSION
Because of its escalating prevalence and the enormous health and economic burden associated to its co-morbidities, such as type 2 diabetes, obesity has become a major societal problem, now recognized as the major preventable risk factor for all-cause mortality (6, 37) , 290 with a nearly 50% more life-years lost compared to other major avertable factors, like smoking. Glitazones, such as RGZ, are synthetic full PPARγ agonists that have been marketed since the early 2000s for the treatment of type 2 diabetes. However, the use of glitazones in diabetic patients has dropped significantly over the past years due to a series of adverse side effects that include bone loss and osteoporosis, as well as fluid retention. Bone loss could be 295 bound to the effect of glitazones on the lineage commitment of mesenchymal stem cells towards osteoblasts and adipocytes, and it has been shown that RGZ suppresses osteoblastogenesis and induces adipocyte differentiation (38) . The development of more balanced partial PPARγ agonists, devoid of the side effects showed by the currently marketed PPARγ full agonists, is considered a major challenge for drug discovery (39) . We provide evidence that 300 Δ 9 -THCA-A is a partial PPARγ agonist, lacking the adverse psychotropic effects of Δ 9 -THC, with a lower adipogenic capacity than glitazones, and endowed also with osteoblastogenesisenhancing properties. In in vivo animal experiments, Δ 9 -THCA-A could successfully prevent adiposity and reversed the metabolic and inflammatory complications associated to dietinduced obesity. 305
Docking and functional analysis revealed that Δ 9 -THCA-A may exert its PPARγ activity by acting at both the canonical and the alternative binding sites of the PPARγ LBD. Δ 9 -THCA-A binds to the alternative site by interacting with Ser342 at the β-sheet (Ω-loop) through its carboxylate group. This may explain the observation that Δ 9 -THCA-A is at least 20-fold more potent than Δ 9 -THC to activate PPARγ (5) . In addition, dietary long-and 310 medium-chain fatty acids, as well as small molecules, also bind to the same amino acid in the alternative site, highlighting the relevance of this site for a wide class of synthetic and natural compounds including acidic cannabinoids (40, 41) . Our data also suggest that Δ 9 -THCA-A may stabilize the Ω-loop region and inhibit phosphorylation of PPARγ Ser273, thus inducing anti-diabetic activity. However, Δ 9 -THCA-A does not affect PPARγ co-regulators interaction, 315
and we cannot discard that Δ 9 -THCA-A could also act as a neutral ligand at the orthosteric site, since most of its activities are inhibited by T0070907. Thus, Δ 9 -THCA-A could compete with RGZ in PPARγ-dependent transcriptional assays (5) , and TR-FRET assays also showed that Δ 9 -THCA-A partially prevented the recruitment of TRAP220 and SMRT induced by RGZ. In this model, Δ 9 -THCA-A could push endogenous fatty acids out of the orthosteric 320 pocket toward the alternative binding site (40) . Nevertheless, it has been shown that others partial agonists such as INT131 and BVT-13 do not induce significant binding or displacement of PPARγ co-regulators (32, 41, 42) . Interestingly, SR2595, an inverse PPARγ agonist that blocks phosphorylation of Ser273, could promote osteoblastogenesis in cultured hMSCs (43) . In summary, our in vitro and in vivo data strongly suggest that the binding of Δ 9 -325 THCA-A to the PPARγ orthosteric site accounts for most of the Δ 9 -THCA-A effects mediated by this nuclear receptor, but signaling through the alternative site could also be of biological relevance. Thus, in lean mice, 317 genes modified by Δ 9 -THCA-A but unaffected by T0070907 were found. Among them, upregulation of genes related with the fatty acid metabolism and downregulation of genes belonging to cGMP-PKG, calcium signaling 330 pathways and muscle tissue development, were identified. Whether this pathway is linked or not to the PPARγ alternative site or to other pathways, such as CB 1 signaling, remains to be investigated.
There is growing evidence of a link between obesity and inflammation, and Δ 9 -THCA-A showed a very potent anti-inflammatory profile in HFD mice. Thus, activation of innate and 335 adaptive immune response has been observed in the fat tissue in obese individuals (44-46), and we identified 70 upregulated genes linked to NF-κB and cytokine-cytokine-receptor signaling, whose expression was largely prevented by treatment with Δ 9 -THCA-A. Within them, T-and B cell markers, as well as macrophage-derived cytokines and chemokines, were identified, showing that both the innate and the adaptive immune responses account for the 340 inflammatory status in the fat tissue of HFD mice. There is strong evidence that PPARγ inhibits NF-κB activation through several mechanisms, repressing NF-κB-mediated transcription of proinflammatory cytokines in immune and non-immune cells (47) . Thus, Δ 9 -THCA-A could dampen inflammation mainly through the PPARγ pathway, and this phytocannabinoid deserves consideration for the management of other chronic or acute 345 inflammatory diseases.
The efficacy of Δ 9 -THCA-A to alleviate a wide spectrum of metabolic and hormonal derangements linked to diet-induced obesity was evaluated in a validated preclinical model of metabolic syndrome, namely, 12-wk exposure to HFD (48) . This model fully recapitulates the cardinal manifestations of obesity and its major complications, including an increase of body 350 weight, fat mass, adipocyte area and adiposity index, accompanied by perturbed glucose homeostasis and insulin resistance, as well as enhanced liver lipid deposition and steatosis.
Notably, a regimen of 3-wk treatment with an effective daily dose of Δ 9 -THCA-A was sufficient to reverse such adverse metabolic profile, causing a marked suppression of body weight gain and adiposity, significantly lowering basal glucose and insulin levels, and fully 355 preventing HFD-induced glucose intolerance and insulin resistance. Moreover, circulating triglyceride levels were reduced and steatosis scores were substantially improved by 3-wk Δ 9 -THCA-A treatment in HFD mice, substantially reversing the metabolic phenotype caused by the high fat content diet. Likewise, the major hormonal and cytokine alterations caused by HFD were reversed by Δ 9 -THCA-A, with a significant decrease in circulating leptin and 360 glucagon, and a significant increase in serum GLP-1 and adiponectin levels. Such a switch towards an anti-inflammatory state was also detected by our adipo-/cytokine arrays, which confirmed the reversal of most of the pro-inflammatory humoral alterations caused by HFD.
Interestingly, the beneficial effects of Δ 9 -THCA-A were not only observed in HFD conditions, but also, albeit to a lesser extent, in lean animals fed a control diet, in which 3-wk treatment 365 with Δ 9 -THCA-A was capable to reduce body weight and adiposity, as well as basal glucose, insulin and triglyceride levels, together with a significant enhancement of glucose tolerance and insulin sensitivity. All these features define an optimal pharmacological profile of Δ 9 -THCA-A for globally handling the metabolic syndrome linked to obesity.
The beneficial effects of Δ 9 -THCA-A on body weight and metabolic status are somewhat 370 at odds with the reported orexigenic and lipogenic activity of cannabinoids (49, 50) . In our studies, Δ 9 -THCA-A failed to cause any detectable change in food intake, supporting a distinct pharmacological profile compared to Δ 9 -THC, whose feeding-promoting effects underlie its use in the management of cachexia (51). The lack of orexigenic effect together with the substantial body weight loss induced by Δ 9 -THCA-A suggests a potential use of this 375 compound to induce adaptive thermogenesis. Indeed, chronic treatment with Δ 9 -THCA-A caused the upregulation of a large set of genes belonging of the thermogenesis pathway, with a prominent increase in the UCP-1 content in inguinal WAT that was largely prevented by cotreatment with the PPARγ inhibitor, T0070907. UCP-1 induction was also detected in the WAT of HFD mice. Altogether, these findings suggest that, acting at least partially via 380 PPARγ, Δ 9 -THCA-A causes browning of the white adipose tissue, and this activity could mechanistically underlie the beneficial effects of this carboxylated cannabinoid on energy and metabolic homeostasis. These features add to our current efforts to identify pharmacological agents capable to activate thermogenesis without undesired side effects.
The global challenge posed by obesity and the inherent difficulties to handle its multi-385 factorial pathophysiology have fueled the search for novel therapeutic agents endowed with multi-target activity and capable to improve the different metabolic alterations associated to overweight. Recent efforts in this area include the development of novel hormonal multiagonists based on peptide chimeras, or on conjugates fusing peptides and small molecules, capable to jointly target the various signaling pathways involved in the pathogenesis of the 390 major complications of obesity (20) . While this approach holds the promise to improve obesity treatments, it is not devoid of potential side effects and the pharmacodynamic limitations linked to the integration of different hormonally-active moieties with, in some cases, opposite biological activities. In the context of a poly-pharmacological approach to obesity and metabolic syndrome, the phytocannabinoid, Δ 9 -THCA-A, deserves further studies, 395 since it is endowed with the beneficial effects of PPARγ agonists but devoid of their adipogenic activity and of the adverse psychotropic and orexigenic effects of narcotic cannabinoids. The effects of the administration of Δ 9 -THCA-A in a preclinical model of dietinduced obesity equal, if not outperform, the results reported for promising poly-agonist therapies recently advocated for obesity treatment (18) (19) (20) , suggesting that this non-400 psychotropic phytocannabinoid, as well as non-decarboxylated Cannabis sativa extracts, are worth of consideration for the management of obesity and metabolic disease. In another set of experiment, eight-week old male C57BL6 mice fed with CD were treated with Δ 9 -THCA-A (20 mg/Kg i.p.), with or without the selective PPARγ inhibitor, T0070907 (5 mg/Kg i.p.), for 3 weeks (n = 10/group). Pair-aged animals treated with vehicle served as 470 control (n= 10/group).
Methods
Δ 9 -THCA-A isolation
Immunohistochemistry and protein analysis by Western Blots.
Liver and iWAT tissues were fixed in formalin for 24 hours, embedded in paraffin and sectioned. Liver tissue sections (5 µm) were stained with haematoxylin and eosin (H&E). 475 Slides were evaluated for steatosis according to the Kleiner system. A semi-quantitative score was assigned to describe the extent of steatosis (0, <5%; 1, 5-33%; 2, 33-66%; and 3, >66%). IHC analysis of iWAT tissue sections (7 µm) was carried out as described previously (48) . Signaling Technology, Danvers, MA, USA). Protein levels were normalized to β-actin (1:5000 dilution, A5060, Sigma Aldrich). Membranes were washed and incubated with the appropriate horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature and detected by chemiluminescence system (GE Healthcare Europe GmbH, Freiburg, Germany). 495
Intraperitoneal glucose and insulin tolerance tests, and triglyceride determinations.
The animals were ip injected with a bolus of 2 g of glucose per kg BW, after a 5 h period of food deprivation, and blood glucose levels were determined at 0, 20, 60 and 120 min after injection. For ITT, the animals were subjected to ip injection of 1 U of insulin (Sigma 500 Aldrich) per kg body weight, after a 5 h fasting. Blood glucose levels were measured at 0, 20, 60 and 120 minutes. All glucose concentrations were measured using a handheld glucometer (Accu-Check Advantage®; Roche Diagnostics, Rotkreuz, Switzerland). In addition, serum triglyceride levels were assayed, using a GPO-POD assay kit (Triglyceride Liquid kit 992320, Quimica Analitica Aplicada SA, Tarragona, Spain). 505 
Determination of hormonal, metabolic and inflammatory markers.
RNA-Seq and bioinformatic analysis
For each group, total RNA was extracted from iWAT, prepared, pooled, and run on an 520
Agilent Bioanalyzer system to confirm quality (RNA integrity number >8). Transcriptome libraries were then constructed using poly-A selection with the TruSeq Stranded mRNA Library Prep Kit (Cat. No. RS-122-2101, Illumina, San Diego, CA, USA). In brief, 300 ng of total RNA from each sample was used to construct a cDNA library, followed by sequencing on the Illumina HiSeq 2500 with single end 50 bp reads and ~30 millions of reads per sample. 525
The FASTQ files were pre-processed with Trimmomatic (v0.36) (52) to remove adapter sequences and aligned to the mm10 assembly of the mouse genome using HISAT2 (v2.1.0) (53). The counts per gene matrix were obtained from the alignments with featureCounts (v1.6.1) (54) using the in-built RefSeq annotation for the mm10 genome assembly. After filtering genes with less than 15 reads across samples, the raw counts were analyzed with 530 DESeq2 (v1.20.0) (55) to obtain the regularized log transformed expression matrix and the differential expression analysis results. We used a threshold of an absolute fold change ≥ 2 and an adjusted P value ≤ 0.01 to consider a gene as differentially expressed in any comparison. Heatmaps were generated using the scaled mean of the regularized log expression for each group with the R package ComplexHeatmap (v1.20.0). The gene set 535 enrichment analysis (GSEA) (56) and the over-representation analysis were performed using the R package ClusterProfiler (v3.10.1) (57). For GSEA, genes were pre-ranked using the log2 transformed fold change. The KEGG pathway database and Gene Ontology (Biological Process) annotation were used to group genes by biological function. All the P values were adjusted using the Benjamini and Hochberg correction to control the false discovery rate 540 (FDR).
Real-time PCR.
Total RNA was isolated at day 7 or 14 of MSCs differentiation using the High Pure RNA Isolation kit (Roche Diagnostics). For tissues, total RNA was isolated using the Qiagen 545
RNeasy Lipid Kit (Qiagen, Hilden, Germany). For real-time PCR analysis, RNA was reverse transcribed to cDNA using the iScript™ cDNA Synthesis Kit (Bio-Rad), and the cDNA generated was analysed by real-time PCR using the iQTM SYBR Green Supermix (Bio-Rad) using a CFX96 Real-Time PCR Detection System (Bio-Rad). Gene expression was normalized to HPRT or GADPH mRNA levels in each sample. The HPRT or GAPDH gene 550 was used to standardize mRNA expression in each sample. The primers used are listed in Supplementary Table S2 .
Statistical analysis.
In vitro data are expressed as mean ± SD with a minimal of 3 to 4 independent experiments. 555
In vivo results are represented as mean ± SEM and the determinations were conducted with a minimal total number of 6-10 animals per group. Statistical analyses were performed on data distributed in a normal pattern, using Student's t tests or ANOVA followed by Tukey's test. P 
